Phillips B B
Univ. of Iowa Hospitals and Clinics, Iowa City 52242, USA.
Pharm Pract Manag Q. 1997 Oct;17(3):21-31.
Metformin and acarbose are novel antihyperglycemic agents indicated for the treatment of non-insulin-dependent diabetes mellitus. These agents offer new therapeutic options to control hyperglycemia that were previously unavailable. Common to both agents is a relatively high incidence of gastrointestinal adverse effects. Initiating therapy at a low dose and slowly titrating to therapeutic response may be the most effective way to minimize associated adverse effects. Recognition and proper management of these possible adverse effects can optimize therapy and maximize the potential for successful outcomes with these agents while limiting drug noncompliance.
二甲双胍和阿卡波糖是用于治疗非胰岛素依赖型糖尿病的新型抗高血糖药物。这些药物为控制高血糖提供了以前无法获得的新治疗选择。这两种药物的共同特点是胃肠道不良反应的发生率相对较高。以低剂量开始治疗并缓慢滴定至治疗反应可能是将相关不良反应降至最低的最有效方法。认识并妥善处理这些可能的不良反应可以优化治疗，并在限制药物不依从性的同时，最大限度地提高使用这些药物取得成功结果的可能性。
